Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1362602

USP

Levonorgestrel

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

D(−)-Norgestrel, 13β-Ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one, 17α-Ethynyl-18-homo-19-nor-testosterone, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-yn-3-one, 18,19-Dinor-4-pregnen-20-yn-3-one, Levonorgestrel

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
797-63-7
Molecular Weight:
312.45
MDL number:
MFCD00199013
UNSPSC Code:
41116107
PubChem Substance ID:
329750050
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levonorgestrel

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H351,H360D,H362

Hazard Classifications

Carc. 2 - Lact. - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Diana Mansour
Contraception, 85(3), 224-234 (2011-11-10)
The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use. The LNG-IUS is typically associated with transient menstrual disturbance during
Elizabeth A McCarthy et al.
Contraception, 86(5), 587-590 (2012-04-14)
Correctly placed levonorgestrel-releasing intrauterine systems (LNG-IUSs) are rarely associated with intrauterine pregnancy when pregnancy occurs. LNG-IUS retrieval, termination of pregnancy and conservative management if retracted strings prevent ready removal are the usual clinical options given to women. The conservative course
Elizabeth G Raymond et al.
Obstetrics and gynecology, 117(3), 673-681 (2011-02-24)
To determine the effectiveness and safety of repeated precoital and postcoital use of levonorgestrel for pregnancy prevention. We searched eight computerized databases for studies that evaluated oral hormones taken for contraception immediately before or after each coital act during one
Woraluk Somboonporn et al.
Menopause (New York, N.Y.), 18(10), 1060-1066 (2011-07-02)
The objective of this study was to compare the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) with those of systemic progestogen in perimenopausal and postmenopausal women taking systemic estrogen therapy (ET). We searched Medline (August 8, 2009), Embase (August 8
Lisa L Bayer et al.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 52(4 Suppl), S54-S58 (2013-04-03)
The levonorgestrel intrauterine system (LNG-IUS) is an underused contraceptive method in adolescent populations. In addition to being a highly effective, reversible, long-acting contraception, the LNG-IUS has many noncontraceptive health benefits including reduced menstrual bleeding, decreased dysmenorrhea and pelvic pain related
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service